Gastroenterology
Peptic Ulcer Disease
12
Pipeline Programs↗
1
Active Trials↗
6
Companies Involved↗
Peptic Ulcer Disease is an emerging landscape with 12 programs across 6 companies. The most active players are Dexcel Pharma Technologies Ltd., Pfizer, Alnylam Pharmaceuticals. 9 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Analysis
Trial Status
5
clinical trials
Unknown status2 · 40%
Completed2 · 40%
Recruiting1 · 20%
Clinical Trials
Trial Activity
Comparison of Conventional Triple Therapy Versus Sequential Therapy for H. Pylori in Peptic Ulcer Disease: Prospective Randomized Trial
Completed·—·Phase 4·NCT01418300·159 enrolled
Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease
Recruiting·—·N/A·NCT07260006·80 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)